Senate Biosimilars Bill Readied For Take-Off In Next Congress
This article was originally published in The Pink Sheet Daily
Executive Summary
Kennedy will enter 111th Congress with a ready-to-go bill after committee officially reports out S. 1695 last week.
You may also be interested in...
Follow The Follow-On Money: Obama’s Budget Has Modest Biogeneric Savings
The fiscal 2010 federal budget outlined by the Obama administration Feb. 25 takes a conservative view of the fiscal benefit of generic biologics - estimating they will contribute $9.2 billion over 10 years to help pay for health care reform
Follow The Follow-On Money: Obama’s Budget Has Modest Biogeneric Savings
The fiscal 2010 federal budget outlined by the Obama administration Feb. 25 takes a conservative view of the fiscal benefit of generic biologics - estimating they will contribute $9.2 billion over 10 years to help pay for health care reform
Big Pharma's March Into Biotech Could Make Big Biologics A Big '09 Theme
In 2009, some of the biggest new drugs might not technically be drugs at all. Major biologic products could dominate the upcoming year, largely thanks to big pharma's maturing interest in biotechnology